DeepMed Research

GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Successful Control and Clinical Effectiveness Of SERETIDE(Salmeterol/Fluticasone Propionate) Study In Asthma.(SUCCESS)

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Salmeterol/ fluticasone propionate

First Posted Date: 2007-05-31

Last Posted Date: 2012-11-12

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 424

Registration Number: NCT00480649

Locations: 🇰🇷
GSK Investigational Site, 전주시, Korea, Republic of

GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer

Phase 3

Terminated

Conditions: Lung Cancer, Non-Small Cell

Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic
Biological: Placebo Control

First Posted Date: 2007-05-30

Last Posted Date: 2020-12-22

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2278

Registration Number: NCT00480025

Locations: 🇬🇧
GSK Investigational Site, Sheffield, United Kingdom

Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese Infants

Phase 3

Completed

Conditions: Infections, Rotavirus
Rotavirus Vaccines

Interventions: Biological: Placebo
Biological: Rotarix

First Posted Date: 2007-05-30

Last Posted Date: 2020-01-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 765

Registration Number: NCT00480324

Locations: 🇯🇵
GSK Investigational Site, Osaka, Japan

A Study Of The Effects Of CB2 Compound Of GW842166 In Patients With Osteoarthritis

Phase 2

Completed

Conditions: Osteoarthritis

Interventions: Drug: GW842166
Drug: Placebo

First Posted Date: 2007-05-28

Last Posted Date: 2017-07-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT00479427

Locations: 🇬🇧
GSK Investigational Site, London, United Kingdom

CONCEPT: A 1-Year Comparison Of A Stable Dose Of SERETIDE® Inhaler With An Adjustable Maintenance Dose Of SYMBICORT® Inhaler. SERETIDE® Inhaler is a Trademark of GSK Group of Companies. SYMBICORT® Inhaler is a Trademark of Astra Zeneca.

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Salmeterol/fluticasone propionate or formoterol/budesonide

First Posted Date: 2007-05-28

Last Posted Date: 2016-09-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 700

Registration Number: NCT00479739

Locations: 🇬🇧
GSK Investigational Site, Fleetwood, United Kingdom

Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer

Phase 2

Terminated

Conditions: Relapsed Breast Cancer
Neoplasms, Breast

Interventions: Drug: Lapatinib
Drug: Capecitabine
Drug: Docetaxel
Drug: nab-Paclitaxel

First Posted Date: 2007-05-28

Last Posted Date: 2012-06-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 9

Registration Number: NCT00479856

Locations: 🇺🇸
GSK Investigational Site, Fairfax, Virginia, United States

Part A: Radiolabel Study With GW786034 Part B: Single Dose of GW786034

Phase 1

Completed

Conditions: Carcinoma, Renal Cell

Interventions: Drug: GW786034, oral
Drug: GW786034, radiolabeled oral
Drug: GW786034, IV

First Posted Date: 2007-05-25

Last Posted Date: 2017-11-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 10

Registration Number: NCT00478725

Locations: 🇺🇸
GSK Investigational Site, Nashville, Tennessee, United States

Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)

Phase 1

Completed

Conditions: Infections, Papillomavirus

Interventions: Biological: GSK Biologicals' HPV vaccine (GSK1674330A)
Biological: Cervarix TM

First Posted Date: 2007-05-25

Last Posted Date: 2017-05-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 540

Registration Number: NCT00478621

Locations: 🇧🇪
GSK Investigational Site, Wilrijk, Belgium

A 2 Part Study Examining Doses Of GSK961081 In Healthy Volunteers And Then In COPD Patients

Phase 2

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK961081

First Posted Date: 2007-05-25

Last Posted Date: 2017-02-02

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 82

Registration Number: NCT00478738

Locations: 🇿🇦
GSK Investigational Site, Mowbray, South Africa

Lapatinib in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer

Phase 2

Completed

Conditions: Neoplasms, Breast
Metastatic Breast Cancer

Interventions: Drug: Lapatinib
Drug: capecitabine

First Posted Date: 2007-05-23

Last Posted Date: 2018-09-17

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 51

Registration Number: NCT00477464

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy